| 摘要 |
Antibodies and other specific binding molecules which bind to insulin-like growth factor-I (IGF-I), particularly the 1-17, 18-21, 22-37, 45-53, 54-60, 59-70 or, especially, the 36-44 region, potentiate or enhance its activity. The antibodies may be generated (in situ) by administering an appropriately antigenic molecule. IGF-I potentiation is useful in a wide range of clinical conditions. |
